{"task_id": "86b39a38e4064418", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 182/464)", "text": "urvival 19 months\n170\nChronic Lymphocytic Leukemia\n\n--- Page 192 ---\nDIAGNOSTIC AND PROGNOSTIC ISSUES (CONT\u2019D)\nBINET STAGING\nA\n<3 lymphoid bearing sites enlarged. Median\nsurvival >10 years\nB\n\u00063 lymphoid bearing sites enlarged. Median\nsurvival 5 years\nC\nanemia ( <100 g/L [10 g/dL]) or\nthrombocytopenia (<100\u0003103/mL). Median\nsurvival 2 years\nADVERSE PROGNOSTIC FACTORS OF CLL\nhigher\nRai stage, high Binet stage, diffuse pattern on bone\nmarrow biopsy, lymphocyte doubling time <1 year\n(5 year survival vs. 12 year survival), CD38+, unmu\ntated IgVH genes, ZAP70 positive, P2X7 receptor, p53\nmutation, gene 1513A/A genotype, 17p deletion, 11q\ndeletion, trisomy 12\nFEATURES\nSUGGESTIVE\nOF\nTRANSFORMA\nTION\nnew onset localized lymph node enlarge\nment, B symptoms (without obvious increase in\ntumor burden), hypercalcemia, elevation in LDH, or\nextranodal disease other than bone marrow and\nliver, rapid increase of splenomegaly, rapid eleva\ntion of lymphocytosis\nMANAGEMENT\nAGE <65 AND OTHERWISE HEALTHY (potentially\ncurative)\nconsider high dose chemotherapy + allo\ngeneic stem cell transplant\nAGE >65 OR COMORBIDITIES (palliative)\nfirst line\nregimens include FR (fludarabine, rituximab) or FCR\n(fludarabine, cyclophosphamide, rituximab). Second\nline therapy includes mainly alkylating agents (chlor\nambucil, cyclophosphamide, CVP). Alemtuzumab\n(anti CD52 antibody) is useful for fludarabine refractory\ndisease (i.e. lack of CR/PR, or response but <6 months).\nIndications for treatment include symptoms (weak\nness, painful lymphadenopathy, B symptoms, sympto\nmatic splenomegaly), anemia (Hb <110 g/L [<11 g/\ndL]),\nthrombocytopenia\n(platelets<100\u0003103/mL),\nautoimmune\nhemolytic\nanemia/thrombocytopenia\nthat failed steroids, progressive disease (increasing lym\nphocytosis with doubling time <6 months \u0004 rapidly\nenlarging lymph nodes, spleen, and liver). Ifevidence of\nMANAGEMENT (CONT\u2019D)\nRichter\u2019s transformation, treat as aggressive lym\nphoma with CHOPR\nNOTE\nwhile traditionally SLL has been managed as\na low grade non Hodgkin\u2019s lymphoma, it is identical\nto CLL and should be treated as such\nTREATMENT ISSUES\nNCI WORKING GROUP DIAGNOSTIC CRITERIA FOR\nTREATMENT RESPONSE\n\u0002\nCOMPLETE RESPONSE\nnormal physical examination\nand no symptoms. Lymphocytes \b4 \u0003103/mL,\nneutrophils \u00061.5\u0003103/mL, platelets >100\u0003103/\nmL, Hb >110 g/L [>11 g/dL], and bone marrow\nlymphocytes < 30% with no nodules. Duration of\nat least 2 months\n\u0002\nPARTIAL\nRESPONSE\nnodes/liver/spleen\n\u000650%\ndecrease PLUS one of neutrophils \u00061.5\u0003103/mL,\nplatelets >100\u0003103/mL, or Hb >110 g/L [>11 g/dL]\nor 50% improvement. Duration of at least 2 months\n\u0002\nSTABLE DISEASE\nbetween PR and PD\n\u0002\nPROGRESSIVE\nDISEASE\nany one of nodes/liver/\nspleen \u000650% increase or new lesions, lymphocytes\n\u000650% increase, or Richter\u2019s syndrome\nSPECIFIC ENTITIES\nHAIRY CELL LEUKEMIA\n\u0002\nPATHOPHYSIOLOGY\nrare indolent non Hodgkin\u2019s\nlymphoma with mononuclear cells displaying cyto\nplasmic projections giving a hairy appearance.\nSecretes fibronectin, cytokines, and TNF causing\nbone marrow fibrosis\n\u0002\nCLINICAL FEATURES\nsplenomegaly (90%), cytope\nnia (fatigue, recurrent infections, thrombocytope\nnia),\nand\nleukocytosis.\nLymphadenopathy\nis\nuncommon\n\u0002\nTREATMENTS\ntreat only if symptomatic (cytope\nnia, splenomegaly, B symptoms). Cladribine\n(2Cda) is first line treatment and may be\nrepeated. Other treatments include pentostatin,\ninterferon, splenectomy, rituximab, and BL22\n(CD22 antibodies)\nHodgkin\u2019s Lymphoma\nPATHOPHYSIOLOGY\nHISTOLOGIC TYPE\n\u0002\nCLASSICAL HODGKIN\u2019S LYMPHOMA (95%)\nB cell lym\nphoma characterized by the presence of Reed\nSternberg cells. CD15 and CD30 positive. Spreads\nin orderly fashion to contiguous nodal regions\nPATHOPHYSIOLOGY (CONT\u2019D)\n\u0002\nNODULAR\nSCLEROSIS (70%)\nmore common\nin females, above diaphragm involvement\n(mediastinal mass). Three grades include\nlymphocyte predominant (G1), mixed (G2),\nand syncytial (G3)\nHodgkin\u2019s Lymphoma\n171", "text_length": 3863, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 182/464)", "type": "chunk", "chunk_index": 181, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.495935", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.496816", "status": "complete", "chunks_added": 2}